Realta Investment Advisors’s BioMarin Pharmaceuticals BMRN Stock Holding History

Realta Investment Advisors’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-173	Closed	-$14K	–	425
2019 Q4	$14K	Buy	173 +130	+302%	+$9.82K	﹤0.01%	1039
2019 Q3	$4K	Sell	43 -50	-54%	-$3.85K	﹤0.01%	1361
2019 Q2	$8K	Buy	93 +40	+75%	+$3.42K	﹤0.01%	1193
2019 Q1	$5K	Buy	+53	New	+$4.91K	﹤0.01%	1062

Other funds holding BMRN

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Realta Investment Advisors's BMRN Position: Q1 2020 in Review

Realta Investment Advisors sold out of BioMarin Pharmaceuticals (BMRN) in Q1 2020, closing a stake of 173 shares — an estimated $14K sold.

Realta Investment Advisors first reported a position in BMRN in Q1 2019 and held it in 4 quarters. The position peaked at $14K in Q4 2019. 500 funds tracked by Wall St. Rank hold BMRN as of Q1 2020.

Realta Investment Advisors reported no remaining BioMarin Pharmaceuticals position as of Q1 2020 after selling out during the quarter.
Realta Investment Advisors sold 173 BioMarin Pharmaceuticals shares in Q1 2020, an estimated $14K.
Realta Investment Advisors first reported a position in BioMarin Pharmaceuticals in Q1 2019 and held it in 4 quarters.
Realta Investment Advisors's BioMarin Pharmaceuticals position peaked at $14K in Q4 2019.
500 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q1 2020.

Based on Realta Investment Advisors's 13F filing for Q1 2020, filed 23 Apr 2020.